{
  "docId": "019de511-2ada-77ca-83e4-0d3611e959dd",
  "docSlug": "485951bf6bd09c0d147151f934d74dce",
  "documentTitle": "Cytek | IPO Presentation Deck | 36 slides",
  "authorId": "cytek",
  "authorName": "Cytek",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 36,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a chevron-based list layout to highlight key company strengths.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de511-2ada-77ca-83e4-0d3611e959dd/4",
  "deckHref": "/decks/019de511-2ada-77ca-83e4-0d3611e959dd",
  "deckJsonHref": "/decks/019de511-2ada-77ca-83e4-0d3611e959dd.json",
  "deckAnchorHref": "/decks/019de511-2ada-77ca-83e4-0d3611e959dd#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. Revenue growth between FY2019 - FY2020. 2. We define Adjusted EBITDA as net income (loss) adjusted for interest expense, interest income, other income (expense), net, provision for (benefit from) income taxes, depreciation and amortization, legal settlement expenses and stock-based compensation expenses. Adj. EBITDA Margin is on a percentage of revenue basis. 3. Reconciliation of Non-GAAP figures are in the appendix. 4. 2024 market projection estimate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a74d8577-7c15-4272-9f50-7545c879e411",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.1,
        "y": 0.41
      },
      "kind": "list",
      "text": "Validated platform with over 210 peer-reviewed publications, which continues to accelerate alongside growing applications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08cbcfe0-b07a-4763-a176-1c8f23ba12a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.1,
        "y": 0.54
      },
      "kind": "list",
      "text": "Delivering rare combination of high revenue growth (60% YoY) with profitability (16% Adjusted EBITDA margins)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ba4b4a7-7aba-4219-a9e6-19685138ecb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.1,
        "y": 0.15
      },
      "kind": "list",
      "text": "Novel, patented FSP platform utilizes the full spectrum of fluorescent signatures to deliver high-resolution, high-content and high-sensitivity cell analysis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f3c84b8-2b81-499d-98e2-76922e2be565",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.1,
        "y": 0.67
      },
      "kind": "list",
      "text": "Potential utility across a myriad of research and clinical applications could allow Cytek to access the broader $23Bn cell analysis market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8652ff56-a4f9-4ba5-8917-fc6fd79e47fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.1,
        "y": 0.28
      },
      "kind": "list",
      "text": "Highly intuitive, integrated workflow solutions driving strong adoption with over 750 instruments placed since commercial launch in 2017",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d962259d-a27f-4b9f-a893-5e779bbdfe11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.1,
        "y": 0.8
      },
      "kind": "list",
      "text": "Comprehensive suite of solutions expands customer base and diversification, and provides recurring revenue opportunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f599a9d3-49fc-4429-bdee-76fc80c57d88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Cytek is Becoming the Premier Cell Analysis Company",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f85c7d6f-364b-48bc-a611-fbe5f35267ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "2066d87a-197e-4057-a988-6c5ecd17b2b1",
      "evidence": "title/headline: Cytek is Becoming the Premier Cell Analysis Company",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 4,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "da176b7d-3633-4047-81f2-67242d6ff6d0",
      "evidence": "The deck presents a brief overview of Cytek's value proposition on page 4",
      "position": 1,
      "objective": "Introduce Cytek's value proposition",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}